BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2019;42:898-902. [DOI: 10.1097/coc.0000000000000620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 George B, Kent M, Surinach A, Lamarre N, Cockrum P. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:754687. [PMID: 34671563 DOI: 10.3389/fonc.2021.754687] [Reference Citation Analysis]
2 Kim SS, Lee S, Seung Lee H, Bang S, Han K, Park MS. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Radiology 2022;:212236. [PMID: 35258374 DOI: 10.1148/radiol.212236] [Reference Citation Analysis]
3 Alpertunga I, Sadiq R, Pandya D, Lo T, Dulgher M, Evans S, Bennett B, Rennert N, Frank RC. Glycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer. Front Oncol 2021;11:571855. [PMID: 33718132 DOI: 10.3389/fonc.2021.571855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Reni M, Peretti U, Zanon S, Macchini M, Balzano G, Mazza E, Tamburrino D, Orsi G, Arcidiacono PG, Falconi M, Gianni L. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2020;85:641-50. [PMID: 32157412 DOI: 10.1007/s00280-020-04047-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]